探讨生血宁片对红细胞生成素治疗中青年肾衰竭期慢性肾脏病患者肾性贫血的影响  

Effect of Shengxuening Tablets combined with erythropoietin in the treatment of young and middle-aged patients with stage V chronic kidney disease with renal anemia

作　　者：刘冰 李桂花 张瑾文 柯亨记 Liu Bing, Li Guihua, Zhang Jinwen, et al.(Department of Nephrology, People＇s Hospital of Yangxin County, Yangxin 435200, China)

机构地区：[1]阳新阳新县人民医院肾病内科,湖北435200

出　　处：《国际泌尿系统杂志》2018年第5期811-814,共4页International Journal of Urology and Nephrology

摘　　要：目的 探讨生血宁片对红细胞生成素治疗中青年肾衰竭期慢性肾病患者肾性贫血的影响.方法 2013年1月至2016年3月,105例中青年肾衰竭期慢性肾病肾性贫血患者按照随机数字表法分为高剂量组、低剂量组和对照组,各35例.对照组行血液透析及红细胞生成素90 IU·（kg·周）-1治疗,低剂量组在对照组的基础上口服生血宁片,高剂量组在红细胞生成素150 IU·（kg·周）-1的基础上口服生血宁片,对比三组治疗前后血红蛋白、红细胞压积及血清铁蛋白、转铁蛋白饱和度、氧自由基、超氧化物歧化酶及临床疗效、研究期间不良反应.结果 三组各剔除2例,99例完成研究;高剂量组、低剂量组总有效率均明显高于对照组（96.97％ vs.81.82％、90.91％ vs.81.82％,P＜0.05）;高剂量组总有效率略高于低剂量组（96.97％ vs.90.91％,P＞0.05）;高剂量组、低剂量组治疗后血红蛋白、红细胞压积及血清铁蛋白、转铁蛋白饱和度、氧自由基、超氧化物歧化酶优于本组治疗前及同期对照组（P＜0.05）,高剂量组、低剂量组无严重药物不良反应;高剂量组治疗后血红蛋白、红细胞压积及血清铁蛋白、转铁蛋白饱和度、氧自由基、超氧化物歧化酶优于低剂量组（P＜0.05）.结论 生血宁片联合高剂量红细胞生成素治疗中青年肾衰竭期慢性肾病患者肾性贫血临床疗效较好,同时还有助于清除血液中的氧自由基. Objective To investigate Shengxuening Tablets conbined with erythropoietin in the treatment of young and middle-aged patients with stage V chronic kidney disease （CKD） with renal anemia.Methods From January 2013 to March 2016,105 young and middle-aged patients with stage V CKD with renal anemia were randomly divided into high dose group,low dose group and control group,35 cases each group.The control group were treated with hemodialysis and erythropoietin 90 IU · （kg · week）-1,the low dose group were orally given Shengxuening Tablets on the basis of the control group,while the high dose group were treated with erythropoietin 150 IU · （kg · week）-1 and orally given Shengxuening Tablets.Comparisons were made among three groups regarding pre-and post-treatment hemoglobin,hematocrit,serum ferritin,transferrin saturation,oxygen free radicals,superoxide dismutase （SOD）,clinical effects,and adverse reactions during the study.Results Each group excluded two patients separately,and 99 completed the study.The overall response rates of the high dose group and the low dose group were obviously higher than the control group （96.97% vs.81.82%,90.91% vs.81.82%,P 〈0.05）.The overall response rate of the high dose group was slightly higher than and the low dose group （96.97% vs.90.91%,P 〉 0.05）.Post-treatment hemoglobin,hematocrit,serum ferritin,transferrin saturation,oxygen free radicals and SOD in the high dose group and the low dose group were superior to pre-treatment ones in the same group and contemporaneous control group （P 〈 0.05）.No serious adverse drug reactions were noted in the observation group.Post-treatment hemoglobin,hematocrit,serum ferritin,transferrin saturation,oxygen free radicals and SOD in the high dose group were superior to pre-treatment ones in the low dose group （P 〈0.05）.Conclusions Shengxuening Tablets combined with high dose erythropoietin for young and middle-aged patients stage V CKD with renal anemia has better clinical effect,while helping scavenge

关 键 词：肾功能衰竭 慢性 肾疾病 贫血 红细胞生成素 

分 类 号：R692.5[医药卫生—泌尿科学]